Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Author:

Kennedy Sidney H.12,Lam Raymond W.32,McIntyre Roger S.1,Tourjman S. Valérie4,Bhat Venkat5,Blier Pierre6,Hasnain Mehrul7,Jollant Fabrice5,Levitt Anthony J.1,MacQueen Glenda M.8,McInerney Shane J.1,McIntosh Diane3,Milev Roumen V.9,Müller Daniel J.1,Parikh Sagar V.110,Pearson Norma L.11,Ravindran Arun V.1,Uher Rudolf12,

Affiliation:

1. Department of Psychiatry, University of Toronto, Toronto, Ontario

2. *Co-first authors.

3. Department of Psychiatry, University of British Columbia, Vancouver, British Columbia

4. Department of Psychiatry, L’Université de Montréal, Montréal, Quebec

5. Department of Psychiatry, McGill University, Montréal, Quebec

6. Department of Psychiatry, University of Ottawa, Ottawa, Ontario

7. Department of Psychiatry, Memorial University, St. John’s, Newfoundland

8. Department of Psychiatry, University of Calgary, Calgary, Alberta

9. Department of Psychiatry, Queen’s University, Kingston, Ontario

10. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan

11. Canadian Pharmacists Association, Ottawa, Ontario

12. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia

Abstract

Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals. Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. “Pharmacological Treatments” is the third of six sections of the 2016 guidelines. With little new information on older medications, treatment recommendations focus on second-generation antidepressants. Results: Evidence-informed responses are given for 21 questions under 4 broad categories: 1) principles of pharmacological management, including individualized assessment of patient and medication factors for antidepressant selection, regular and frequent monitoring, and assessing clinical and functional outcomes with measurement-based care; 2) comparative aspects of antidepressant medications based on efficacy, tolerability, and safety, including summaries of newly approved drugs since 2009; 3) practical approaches to pharmacological management, including drug-drug interactions and maintenance recommendations; and 4) managing inadequate response and treatment resistance, with a focus on switching antidepressants, applying adjunctive treatments, and new and emerging agents. Conclusions: Evidence-based pharmacological treatments are available for first-line treatment of MDD and for management of inadequate response. However, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.

Publisher

SAGE Publications

Subject

Psychiatry and Mental health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3